Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC

Writer,

Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 8200p (from 8000p).

Broker Forecasts data provided by www.sharesmagazine.co.uk


Related content

Broker Forecast - UBS issues a broker note on AstraZeneca PLC

UBS today reaffirms its sell investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7300p (from 6000p).

Broker Forecasts data provided by...

Thu, 04/06/2020 - 11:40


Broker Forecast - Bryan Garnier issues a broker note on AstraZeneca PLC

Bryan Garnier today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 9100p (from 8780p).

Broker Forecasts data provided...

Tue, 02/06/2020 - 10:10


AstraZeneca cancer drug wins marketing approval in US; heart disease treatment approved in US

Pharma giant AstraZeneca said its cancer drug had been recommended for marketing authorisation in the European Union to treat patients with metastatic pancreatic cancer.

The...

Mon, 01/06/2020 - 07:37


AstraZeneca, Daiichi Sankyo report positive trial results for gastric cancer drug

Pharmaceutical company AstraZeneca said a venture with Daiichi Sankyo had recorded positive clinical trial results for a gastric cancer treatment.

The trial showed that the...

Fri, 29/05/2020 - 14:56


AstraZeneca lung cancer drug cuts risk of disease recurrence or death by about 80%

Pharma giant AstraZeneca said a clinical trial of a drug to treat non-small cell lung cancer reduced the risk of disease recurrence or death by...

Fri, 29/05/2020 - 08:09